Investigating the association of inflammatory markers with clinical outcomes of patients with KRAS and BRAF V600E-mutated colorectal cancer.

200 Background: Patients with colorectal cancer (CRC), particularly those with BRAF and KRAS mutations, often present with high inflammatory markers such as elevated WBC and platelet counts. However, it is unknown whether these inflammatory markers are associated with clinical outcomes of patients with KRAS and BRAF V600E-mutated CRC. In this study, we investigated the potential biomarker role of inflammatory markers in these subgroups of CRC. Methods: We evaluated patients with MSS metastatic CRC (mCRC) at our institution, we included 271 patients with KRAS-mutated and 32 with BRAF V600E–mutated mCRC. Demographic and clinical, laboratory, and molecular data were retrieved by electronic medical records review. Cox proportional hazards regression and Kaplan-Meier survival analyses were performed to assess the association of these factors with overall survival (OS), with statistical significance determined by a p-value threshold of